FDA clears Breztri for asthma and adds a lower-warming propellant
Approved on 8 October, the triple inhaler gains a maintenance asthma use for ages 12 and up. In two trials it beat a two-drug inhaler on lung function, but not on severe flare-ups.
Triple inhaler therapy cuts COPD flare-ups more than two-drug inhalers
Two large trials, ETHOS and IMPACT, found adding an inhaled steroid to a two-bronchodilator inhaler lowered exacerbation rates in COPD — at the cost of more pneumonia.
Four trials ended the case for treating mild asthma with a reliever inhaler alone
Adding an inhaled steroid to the as-needed inhaler roughly halved severe attacks against a short-acting reliever, at a fraction of the daily steroid exposure that maintenance therapy delivers.